Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

2025-03-13 03:45:02 ET

Summary

• Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus.
• Besides a diverse drug portfolio across multiple segments, they have a robust drug discovery pipeline to meet future clinical demand.
• The firm has been a proven cash flow generator, with an above-average dividend yield above +4%, and modest leverage risk.
• Some challenges are the stock appears overvalued on forward earnings multiple, and could use improvement to its profit margin compared to big pharma peers.

Intro: A Japan-Based, Global Pharma Solutions Brand

For today's article, I went venturing into the pharmaceuticals sector again and found a major pharma company trading for just under $15, with a dividend yield above 4%.

Takeda Pharmaceutical ( TAK ) (TKPHF) is a Tokyo-based company that "offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience," according to its SA profile.

Though the company has too vast of a drug portfolio to list it all, just as an example of clinical areas it serves, for US patients the company's website boasts of its strides in the gastroenterology segment , saying it has "made significant strides in developing treatments for patients," with some of their focus areas being "celiac disease and other gastrointestinal inflammatory diseases."...

Read the full article on Seeking Alpha

For further details see: